GlassScriptPhysician profile
Douglas A Fullington
NPI 1730148180
$1,370.20
in general payments reported to CMS, 2019-2025
23 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $26.24 · 2021: $290 · 2022: $177 · 2023: $178 · 2024: $266 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $211.60 | 2019-2023 | Shingrix, Bexsero, Trelegy Ellipta |
| Abbott Laboratories | $97.45 | 2019-2024 | Freestyle Libre 3, Penta |
| Pfizer INC. | $96.82 | 2023-2025 | |
| Novo Nordisk INC | $88.63 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Siemens Medical Solutions USA, INC. | $55.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $36.30 | 2019-2025 | Spravato |
| Antares Pharma, INC. | $34.06 | 2024 | Xyosted |
| Coloplast Corp | $33.39 | 2021 | |
| Mayne Pharma Commercial LLC | $24.75 | 2025 | |
| Recor Medical INC | $20.60 | 2025 | Paradise Ultrasound Renal Denervation System |
| Teva Pharmaceuticals USA, INC. | $18.81 | 2019 | |
| Dexcom, INC. | $18.04 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $17.57 | 2024 | Krystexxa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $16.30 | 2019 | |
| Lilly USA, LLC | $14.15 | 2022 | |
| Genentech USA, INC. | $12.52 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Fullington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.